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Optimized Analytical Procedures for the
Untargeted Metabolomic Profiling of Human
Urine and Plasma by Combining Hydrophilic
Interaction (HILIC) and Reverse-Phase Liquid
Chromatography (RPLC)–Mass Spectrometry*□S
Ke´vin Contrepois, Lihua Jiang, and Michael Snyder‡
Profiling of body fluids is crucial for monitoring and dis-
covering metabolic markers of health and disease and for
providing insights into human physiology. Since human
urine and plasma each contain an extreme diversity of
metabolites, a single liquid chromatographic system
when coupled to mass spectrometry (MS) is not sufficient
to achieve reasonable metabolome coverage. Hydrophilic
interaction liquid chromatography (HILIC) offers comple-
mentary information to reverse-phase liquid chromatog-
raphy (RPLC) by retaining polar metabolites. With the ob-
jective of finding the optimal combined chromatographic
solution to profile urine and plasma, we systematically
investigated the performance of five HILIC columns with
different chemistries operated at three different pH
(acidic, neutral, basic) and five C18-silica RPLC columns.
The zwitterionic column ZIC-HILIC operated at neutral pH
provided optimal performance on a large set of hydro-
philic metabolites. The RPLC columns Hypersil GOLD and
Zorbax SB aq were proven to be best suited for the met-
abolic profiling of urine and plasma, respectively. Impor-
tantly, the optimized HILIC-MS method showed excellent
intrabatch peak area reproducibility (CV < 12%) and good
long-term interbatch (40 days) peak area reproducibility
(CV < 22%) that were similar to those of RPLC-MS pro-
cedures. Finally, combining the optimal HILIC- and
RPLC-MS approaches greatly expanded metabolome
coverage with 44% and 108% new metabolic features
detected compared with RPLC-MS alone for urine and
plasma, respectively. The proposed combined LC-MS ap-
proaches improve the comprehensiveness of global met-
abolic profiling of body fluids and thus are valuable for
monitoring and discovering metabolic changes associ-
ated with health and disease in clinical research
studies. Molecular & Cellular Proteomics 14: 10.1074/
mcp.M114.046508, 1684–1695, 2015.
Metabolomics is a relatively recent “omic” that aims at
measuring the quantity of a large collection of metabolites (i.e.
low-molecular-weight organic compounds, typically  1,500
Da). It is often applied to the study of human diseases (1, 2)
(i.e. characterization of deregulated metabolic pathways and
discovery of therapeutic targets and biomarkers), drug toxicity
and efficacy (3), and environmental exposure (e.g. food (4, 5))
and lifestyle (e.g. fitness (6)) on health. Metabolomics is ad-
vantageous over other “omics” (i.e. genomics, transcriptom-
ics, and proteomics) because it measures a more direct func-
tional readout of activity and phenotype (7). When applied to
biofluids (i.e. urine and blood), the profiling of metabolites
reveals a snapshot of the “metabolic status” of the subject
and as such holds great promise for personalized metabolo-
mics and medicine (8, 9).
Metabolic profiling studies are mostly performed using i)
chromatography coupled to mass spectrometry (MS) instru-
ments, including gas chromatography (GC)-MS and liquid
chromatography (LC)-MS, as well as ii) nuclear magnetic res-
onance (NMR) spectroscopy platforms. Few studies have
highlighted the benefit of combining multiplatform ap-
proaches for the analysis of urine and blood (10–12). How-
ever, due to instrumentation limitation, most laboratories use
a single analytical approach. Because of its high sensitivity
and wide range of metabolites that can be analyzed, LC-MS
utilization has expanded rapidly over the past 10 years (13).
Most untargeted studies are performed using reverse-phase
liquid chromatography (RPLC, mainly C18-bonded silica col-
umns) because it generates reproducible data for a large set
of metabolites (non- and moderately polar compounds) (14,
15). However, many metabolites in biofluids are water soluble,
polar, and ionic (e.g. amino acids, organic acids, sulfates, and
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sugars) and are usually not retained on RPLC columns, thus
hindering their identification and accurate quantification
(16, 17).
Hydrophilic interaction liquid chromatography (HILIC)1 is
now becoming popular as it offers a complementary selectiv-
ity to RPLC (18–21). A plethora of HILIC stationary phases
have been developed and can be separated in four catego-
ries: i) anionic (mostly bare silica), ii) cationic (silica derivatized
with a positively charged chemical group, mostly aminopro-
pyl), iii) uncharged (silica derivatized with an uncharged chem-
ical group, mostly amide), and iv) zwitterionic (silica deriva-
tized with a chemical group bearing a positive and a negative
charge, mostly sulfobetaine). The different HILIC stationary
phases and their use have been extensively reviewed (22–24).
HILIC methodologies have mostly been optimized for targeted
analyses focusing on a small subset of metabolites (i.e.
nucleosides and derivatives (25), neurotransmitters (26), and
peptides (27)). Despite its usefulness for targeted analyses,
HILIC-MS still represents a challenge in untargeted metabolic
profiling studies because it is less reproducible (retention time
and MS signal drift with time) and requires longer equilibration
time than RPLC-MS (19, 20). As such, less than 15% of the
LC-MS-based untargeted metabolomic studies performed on
biofluids published in 2013 used both HILIC- and RPLC-MS
(28–32). Among these studies, there was no consensus on the
analytical procedure (column and chromatographic conditions)
that will produce the optimal reproducibility and metabolome
coverage for the global analysis of urine and blood.
In this context, we systematically investigated the perform-
ance of a variety of HILIC and RPLC columns under different
chromatographic conditions using standard mixtures and bi-
ological samples. After having determined the optimal chro-
matographic solution for profiling metabolites from urine and
plasma using HILIC- and RPLC-MS, we estimated the intra-
and long-term (40 days) interbatch reproducibility of retention
time and peak area of the optimized LC conditions. Adequate
equilibration and conditioning of the HILIC column resulted in
excellent reproducibility similar to RPLC-MS approaches. Fi-
nally, we investigated the complementarity of HILIC and
RPLC in positive and negative electrospray ionization (ESI)
modes and found that the optimized HILIC condition greatly
expanded the metabolome coverage with 44% and 108%
new metabolic features detected, compared with RPLC-MS
alone in urine and plasma, respectively.
EXPERIMENTAL SECTION
Chemical Material and Standard Sample Preparation—Analytical
grade standards were purchased from various companies as detailed
in the supplementary Excel file S1. Four standard mixtures containing
a total of 174 diverse compounds were prepared for HILIC-MS at a final
concentration of 10 M in 50% acetonitrile. For RPLC, one standard
mixture containing 22 compounds was prepared at a final concentration
of 10 M in 5% acetonitrile. Ammonium acetate, ammonium hydroxide,
formic acid, and acetic acid were purchased from Sigma Aldrich (St.
Louis, MO, USA). MS-grade water, acetonitrile, andmethanol were from
Fischer Scientific (Morris Plains, NJ, USA).
Biological Material and Sample Preparation—Residual blood and
urine samples were obtained from de-identified donors under in-
formed consent approved by Stanford’s Institutional Review Board.
After collection, urine samples were immediately centrifuged at
21,000g for 10 min at 4 °C. The supernatant was aliquoted and stored
at 80 °C prior to analysis. Urine samples were diluted by a factor of
four with 75% acetonitrile and 100% water for HILIC- and RPLC-MS
experiments, respectively. Blood was obtained from the Stanford
Blood Center. Plasma was prepared from whole blood treated with
anti-clot EDTA and kept at 4 °C for 2 h before being aliquoted and
stored at80 °C. Plasma was treated with four volumes of a acetone:
acetonitrile:methanol (1:1:1, v/v) solvent mixture, mixed for 15 min at
4 °C and incubated for 2 h at20 °C to allow protein precipitation (8).
The supernatant was collected after centrifugation at 10,000 rpm for
10 min at 4 °C and evaporated to dryness. The dry extracts were
reconstituted with 50% methanol before analysis.
Instrumentation and LC-MS Acquisitions—Standard mixtures,
urine and plasma samples were analyzed using an Agilent 1260
Infinity HPLC system coupled to an Agilent 6538 UHD Q-TOFMS. The
Q-TOF was equipped with an ESI probe and operated in positive and
negative modes using the MS full scan mode. The data were acquired
between 50 and 1,000 m/z at a scan rate of 1.5 spectra/s in centroid
mode at a resolution of 10,000 (m/z 127). The source conditions were
as follow: gas temperature 325 °C, drying gas 9 l/min, nebulizer 45
psig, fragmentor 125 V, skimmer 47 V and capillary voltage 3,500V or
3,500V in positive or negative ESI modes, respectively. Reference
masses 121.0509 (Purine) and 922.0098 (hexakis(1H, 1H, 3H-tetra-
fluoropropoxy)phosphazine, HP-0921) in positive mode and 112.9856
(TFA anion) and 980.0164 (HP-0921 acetate) in negative mode were
used for internal mass calibration during the runs.
Chromatographic Conditions—Five HILIC columns were compared:
BEH (Ethylene Bridged Hybrid) amide, BEH HILIC, Hypersil GOLD
HILIC, Syncronis HILIC, ZIC-HILIC (see the supplementary experi-
mental section for more details). Mobile phases for HILIC at neutral
pH 6.9 consisted of 10 mM ammonium acetate in 5/95 acetonitrile/
water (A) and 10 mM ammonium acetate in 95/5 acetonitrile/water (B).
Mobile phases A and B were modified with 0.1% formic acid for acidic
pH 3.4 conditions and with 0.5% of 25% ammonium hydroxide for
basic pH 10.15 conditions. The pH was measured in absence of
acetonitrile. Metabolites were eluted from the columns at 0.5 ml/min
using a 1–50% phase A gradient over 15 min. Before each injection,
the column was equilibrated for 5 min with 1% phase A. The oven
temperature was set to 40 °C, and the injection volume was 5 l. Five
RPLC columns were compared: Hypersil GOLD, Hypersil GOLD aq,
BEH C18, Kinetex, and Zorbax SB (see the supplementary experi-
mental section for more details). Mobile phases for RPLC consisted of
0.06% acetic acid in water (A) and MeOH containing 0.06% acetic
acid (B). Metabolites were eluted from the column at a flow rate
leading to a backpressure of 260–280 bar at 99% phase A. A 1–80%
phase B gradient was applied over 9–10 min (see the supplementary
experimental section). The oven temperature was set to 60 °C and the
injection volume was 5 l.
Data Processing and Analysis—Metabolic features (characterized
by a unique mass/charge ratio and retention time) were extracted with
the MassHunter Qualitative Analysis Software B.05.00 (Agilent Tech-
nologies, Santa Clara, CA) with an absolute height filter set to 10,000
counts. A scoring system was created to assign a score to standards
and metabolic features from biological samples. The scoring system
takes into account the retention time, peak shape, and MS signal (see
1 The abbreviations used are: HILIC, hydrophilic interaction liquid
chromatography; RPLC, reverse-phase liquid chromatography;
HMDB, human metabolome database.
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the supplementary experimental section for details). When the score
was not calculated, metabolic features were extracted with the XCMS
(various forms (X) of chromatography mass spectrometry) (33) pack-
age (version 1.39.4) in R (version 3.0.1) with an absolute height filter
set to 2,000 counts. Grouping and annotation were performed with
the CAMERA (34) package (version 1.16.0). The parameters used in
XCMS and CAMERA are detailed in the supplementary experimental
section. Features were putatively identified by matching the accu-
rate masses ( 5 ppm) against a local database containing 33,442
entries generated by Creek et al., (35) with slight modifications.
RESULTS
Optimization of the HILIC-MS Analytical Procedure
Five different HILIC columns were examined; two columns
were composed of uncharged stationary phases (BEH amide
and Hypersil GOLD HILIC), one column was anionic (BEH
HILIC), and two were zwitterionic (Syncronis HILIC and ZIC-
HILIC). Bare silica, amide, and zwitterionic columns were
selected for their complementarity of selectivity toward a wide
variety of compounds (26, 27, 36, 37). We did not assay the
performance of a cationic column containing an aminopropyl
group (such as Luna NH2) due to its reported shorter life time
(22, 28, 38). The tested columns were operated at three
different pH conditions: i) acidic (pH 3.4), ii) neutral (pH 6.9),
and iii) basic (pH 10.15). Only the BEH amide column was
subjected to basic pH because the stationary phases of the
other columns were not stable above pH 8–9. Altogether, 11
chromatographic conditions were run in both positive and
negative ESI modes and compared using standards com-
monly found in biofluids and human urine samples.
Performance of the HILIC Conditions Using Standards—To
facilitate the comparison of the different chromatographic
conditions, we first analyzed a complex mixture of 46 impor-
tant metabolites with diverse chemical properties (Excel file
S1). A qualitative scoring system that assigns a score to each
metabolite was created. The score was calculated based on
the retention time, peak shape, and MS signal and catego-
rized all metabolites into three groups: “good” (green), “ac-
ceptable” (yellow), and “unacceptable” (red). A feature with a
good score will: i) retain on the column to avoid ion suppres-
sion in the void volume zone; ii) have a narrow elution profile
to provide optimal sensitivity and facilitate accurate peak
integration; and iii) have an intense MS signal to be accurately
extracted, aligned, quantified, and identified. A feature was
categorized as acceptable if one of these parameters was not
fulfilled. The remaining metabolites were classified as unac-
ceptable, usually because of broad or multiple peaks or low
signal intensity. Of the 46 standards, three (e.g. adenosine,
adenine, and uridine) were excluded from this analysis be-
cause they were poorly retained and eluted as broad peaks in
all the tested HILIC conditions. Overall, the zwitterionic col-
umn ZIC-HILIC operated at neutral pH was superior for sep-
arating the 43 tested standards because 100% had a good or
acceptable score (Fig. 1A). In comparison, 67% had a good or
acceptable score with BEH HILIC in acidic conditions. Some
representative examples are presented in Fig. S1. Baseline
separation of L-leucine and L-isoleucine could only be
achieved with the ZIC-HILIC column as was the case for
glucose 1-phosphate and glucose 6-phosphate. Similarly, the
acidic amino acids (aspartic and glutamic acids) and cystine
(oxidation of two cysteine molecules) were only well resolved
using the ZIC-HILIC column.
Performance of the HILIC Conditions Using Human Urine
Samples—We next compared the performance of the same
11 chromatographic conditions in positive and negative ESI
modes using urine samples known to contain a great com-
plexity of hydrophilic metabolites. The objective was to max-
imize the number of detected metabolic features (character-
ized by a unique mass/charge ratio and retention time) with a
good or acceptable score. Among all conditions tested, the
ZIC-HILIC column operated at neutral pH provided the best
performance with the highest number of metabolic features
with a good or acceptable score (4,549) (Fig. 1B). This con-
dition was better than BEH amide and BEH HILIC operated at
neutral pH, which yielded 4,306 and 4,141 metabolic features
with the same scores, respectively. Interestingly, all the tested
columns were more efficient at neutral pH than in acidic
conditions, and it was more prominent in negative than in
positive ESI mode (Fig. S2). The number of metabolic features
is known to be a relevant measure of the coverage of a
metabolome (28). Importantly, among 9,862 metabolic fea-
tures extracted with XCMS from a urine sample injected onto
a ZIC-HILIC column operated at neutral pH, 2,395 were pu-
tatively identified by matching our local database ( 5 ppm).
In contrast, BEH amide and BEH HILIC at neutral pH led to the
putative identification of 2,163 and 2,235 metabolic features,
respectively. Accurate quantification and identification require
optimization of the chromatographic separation to minimize
ion suppression and mass spectral complexity. Among all the
tested columns, fewer features eluted in the void volume zone
at neutral pH with ZIC-HILIC (Fig. 1C and Fig. S2). Altogether,
the ZIC-HILIC column operated at neutral pH provided the
optimal results for maximizing the number of hydrophilic me-
tabolites profiled in urine.
Further optimizations were performed by modifying: i) the
organic gradient slope using two mobile phases A with differ-
ent concentration of acetonitrile while running the same pro-
gram (10 mM ammonium acetate in 5/95 acetonitrile/water ver-
sus 10mM ammonium acetate in 50/50 acetonitrile/water), ii) the
oven temperature (20 °C versus 40 °C), and iii) the flow rate (0.5
ml/min versus 0.6 ml/min). The best condition was phase A: 10
mM ammonium acetate in 50/50 acetonitrile/water, oven tem-
perature 40 °C and flow-rate 0.5 ml/min (Fig. S3). Interestingly,
very few metabolic profiling studies of urine and plasma were
performed using a ZIC-HILIC column, and they all used acidic
solvents by adding 0.1% formic acid (39–41). In our experience,
using solvents at neutral pH was clearly superior. We also
observed that ZIC-HILIC column operated at acidic pH pro-
duced better results when 0.2% acetic acid was added to the
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FIG. 1. Optimization of the HILIC-MS analytical procedure. (A) Individual scores of standards under the different HILIC conditions (related
to Fig. S1). The best score in positive and negative ESI modes was selected. (B) Score of the metabolic features from a urine sample under
the different HILIC conditions. Metabolic features from positive and negative ESI modes were combined (related to Fig. S2). (C) Repartition of
the metabolic features (combination of positive and negative ESI modes) along the chromatographic runs (related to Fig. S2).
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mobile phases instead of 0.1% formic acid (Fig. S4). Overall, our
optimized HILIC-MS procedure provided optimal performances
on a large set of hydrophilic standards and enabled the most
“comprehensive” analysis of urine samples with the highest
number of metabolic features with good or acceptable score as
well as the most spread repartition of these features along the
chromatographic gradient.
Suitability of the Optimized HILIC-MS Procedure for the
Untargeted Analysis of Hydrophilic Metabolites in Urine
and Plasma
In order to gain a preliminary view of the metabolite chem-
ical classes that populate urine and blood, we generated a list
of metabolites labeled as detected and quantified in urine,
blood, or both in the Human Metabolome Database (HMDB,
April 2013). Metabolites with a calculated logP above 3 (likely
not retained on the ZIC-HILIC column), inorganic compounds,
and metabolites with a mass below 50 Da and above 1,000 Da
were excluded from this list. The final list contained 916
unique metabolites among which 272 were found exclusively
in urine, 223 in blood, and 421 in both (Excel file S2). It
appears that organic acids and derivatives as well as amino
acids and conjugates are the two most important chemical
classes in urine and blood (Fig. 2).
In order to closely mimic the proportion of metabolites
within each chemical classes reported in urine and blood,
three other standard mixtures were prepared in addition to the
one used above (Excel file S1). Among 174 standards, 37
were excluded from the analysis because they were poorly
retained on the ZIC-HILIC column (i.e. elution in the void
volume zone). These compounds belonged to the following
chemical classes: steroids and derivatives, fatty acids and
conjugates, most pyridines and derivatives, and most indoles
and derivatives. Application of the scoring system showed
that the optimized HILIC-MS method performed very well
for most of the tested metabolites with 126 out of 137 (93%)
exhibiting a good or acceptable score (Fig. 2). Amino acids
and conjugates, carbohydrates and conjugates, alcohols
and polyols, acyl carnitines, peptides, imidazoles and de-
rivatives, and pteridines and derivatives were particularly
well resolved. The compounds with unacceptable scores
eluted as broad multiple peaks. Overall, the optimized HILIC
procedure is well suited to profile a wide range of hydro-
philic metabolites representative of urine and blood com-
positions. Importantly, many of the compounds that were
not well retained or had unacceptable scores were retained
and well resolved with the optimized RPLC conditions (see
below).
Optimization of the RPLC-MS Analytical Procedure
Although numerous companies manufacture C18-bonded
silica columns, the selectivity of non- and moderately polar
compounds can vary greatly depending on the density of C18
alkyl chains, the accessibility of silanol, or the presence of
bonding groups between the silica beads and C18 alkyl
groups (42). The use of the latter enables a better retention of
some polar compounds while conserving RPLC advantages.
Among this type of column, BEH C18 and HSS T3 columns
are very popular for the global metabolomic profiling of urine
(43, 44) and blood (45, 46).
Performance of the RPLC Columns Using Standards—The
performance of five C18-bonded silica RPLC columns were
compared using 22 standards (Excel file S1): Hypersil GOLD,
Hypersil GOLD aq, Kinetex, BEH C18, and Zorbax SB aq. The
tested compounds had increasing calculated logP values
ranging from 4.0 (cAMP) to 6.6 (ursolic acid). Despite similar
composition, the different C18 columns had very distinct se-
lectivities. The two most highly hydrophobic standards (eico-
sapentanoic acid and ursolic acid) were only eluted from the
Zorbax SB aq column, indicating that its stationary phase was
less hydrophobic than the others (Fig. 3A). 13-OxoODE was
not eluted from Hypersil GOLD and Hypersil GOLD aq col-
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umns, indicating that they were the most hydrophobic col-
umns. In contrast, BEH C18 and Kinetex had intermediary
hydrophobicity. When eluted from the column, all the ana-
lyzed compounds had a good or acceptable score under all
the chromatographic conditions.
Performance of the RPLC Columns Using Human Urine and
Plasma Samples—We next compared the performance of the
RPLC columns for the untargeted metabolomic profiling of
urine and plasma samples. The two most hydrophobic col-
umns (Hypersil GOLD, and Hypersil GOLD aq) enabled the
analysis of more metabolic features with a good or acceptable
score (1,746 and 1,635, respectively) from urine in positive ESI
mode (Fig. 3B). BEH C18 and Kinetex columns had interme-
diary performances with 1,131 and 1,360 good or acceptable
features whereas Zorbax SB aq yielded the fewest features.
Among the two best columns, fewer metabolic features eluted
in the void volume zone with Hypersil GOLD than with Hyper-
sil GOLD aq, suggesting that the former was better for optimal
peak separation (Fig. 3C). Thus, Hypersil GOLD performed the
best for the untargeted analysis of urine among the tested
columns. This result is likely due to the expectation that most
urine metabolites are moderately hydrophobic and thus likely
to be better retained on a highly hydrophobic column (12).
Despite the popularity of BEH C18 column for the global
metabolic profiling of urine (43, 44), the number of putatively
identified features was substantially higher with Hypersil
GOLD (1,654 versus 1,219 in positive mode).
The RPLC columns were also compared for their perfor-
mance in analyzing plasma samples. Zorbax SB aq enabled
the analysis of the highest number of features with a good or
acceptable score (840) (Fig. 3D). BEH C18 and Kinetex col-
umns yielded 626 and 701 metabolic features with the same
scores, respectively. Moreover, a limited amount of features
eluted in the void volume zone with Zorbax SB aq (Fig. 3E).
Altogether, Zorbax SB aq column produced the best results to
profile plasma metabolites among the tested RPLC columns.
This result might be expected since a large proportion of
blood metabolites are very hydrophobic (fatty acids, lipids,
and steroids) and will not be eluted from the other more
hydrophobic columns (11). Overall, optimal profiling of urine
and blood metabolites required different RPLC columns.
Intra- and Long-Term Interbatch Reproducibility of the
Optimized HILIC- and RPLC-MS Procedures
Generating reproducible results is key to successful com-
prehensive metabolomic profiling studies. In particular, the
retention time must be stable for accurate peak alignment and
peak selection, and the MS signal must be reproducible for
accurate statistical analysis. RPLC-MS is considered more
robust than HILIC-MS; hence, the former is often used alone
for large-scale untargeted metabolomic studies (43–46), but
the metabolome coverage is not optimal. It is known that
HILIC requires more equilibration time than RPLC (19, 20).
Using 2D principal component analysis plots, we found that
that ZIC-HILIC column was adequately equilibrated and con-
ditioned after the injection of 12 biological samples (Fig. S5A).
Injecting blanks instead of samples did not equilibrate the
system because 12 samples were necessary before acquisi-
tion of reproducible data (Fig. S5B). Injection of five biological
matrixes sufficed to equilibrate RPLC-MS systems (data not
shown).
Intrabatch Reproducibility—To evaluate intrabatch reten-
tion time and peak area reproducibility, the same urine (ZIC-
HILIC and Hypersil GOLD columns) or plasma sample (Zorbax
SB aq) was injected 10 times consecutively after adequate
equilibration and conditioning. For HILIC-MS, the retention
time deviation was very small with a maximum shift of 2 s for
a run that lasts 20 min ( 1% variation) (Fig. 4A and Fig. S6A).
This deviation was consistent between three independent
experiments and was very similar to that obtained with the
two RPLC methods (i.e. Hypersil GOLD and Zorbax SB aq),
which had maximum retention time deviations of 7 s and 2 s,
respectively ( 1% variation) (Fig. 4A and Figs. S6B and S6C).
The intrabatch peak area reproducibility of HILIC-MS was also
excellent with an average coefficient of variation (CV) of
11.4%  0.9% (Fig. 4B) even though the range of metabolite
abundances was very wide (order of magnitude 5  104)
(Fig. S7A). These values were similar to that obtained with the
RPLC methods where the average CVs were 8.7%  0.3%
and 11.8%  1.1% for Hypersil GOLD and Zorbax SB aq
columns, respectively (Fig. 4B). In summary, after adequate
equilibration and conditioning intrabatch reproducibility of the
HILIC-MS method was excellent and similar to RPLC-MS
procedures.
Long-Term Interbatch Reproducibility—Interbatch repro-
ducibility is very important for large-scale untargeted metabo-
lomic studies that involve thousands of samples from longi-
tudinal experiments. For such studies, it is inevitable to
process the samples in different batches before combining
the data for statistical analysis (47). We therefore assessed
the long-term interbatch reproducibility of HILIC- and
RPLC-MS (i.e. Hypersil GOLD) procedures by injecting the
same urine sample 42 and 38 days after an initial analysis,
respectively. The columns were moderately used between the
two batches with the interim injection of 70 samples (stand-
ards and biological samples). Retention time deviation was
maximum 12 s (1% variation) for HILIC-MS and was very
similar to that obtained with Hypersil GOLD column (16 s
corresponding to 1.1% variation) (Fig. 4A). Despite a higher
retention time variation than that calculated for intrabatch
analysis, peak alignment was not impaired. The peak area
reproducibility of the optimized HILIC-MS system was good
with an average CV of 22.0%, and 70.4% of the metabolic
features had a CV  25%. RPLC-MS (Hypersil GOLD) was
more robust with an average CV of 15.0% and 84.7% of the
features had a CV  25% (Fig. 4B). We also analyzed MS
signal variability of a plasma sample injected onto Zorbax
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SB aq column 71 days after an initial analysis and found
slightly higher variability (average CV of 21.0% and 70.2%
of the metabolic features had a CV  25%) presumably
because of independent metabolite extraction, and in-
creased time in storage. Although the long-term interbatch
variation of peak area for HILIC-MS was greater than its
intrabatch variation, the proportion of reproducible meta-
bolic features was similar to previously reported intrabatch
peak areas CVs (28, 48, 49). Altogether, analyzing urine and
plasma samples within 40 days with the optimal HILIC- and
RPLC-MS procedures enabled acquisition of highly repro-
ducible data.
Combination of HILIC- and RPLC-MS in Positive and
Negative ESI Modes and Expansion of the Metabolome
Coverage of Human Urine and Plasma
The complementarity between HILIC and RPLC modes was
evaluated using the accurate mass ( 10 ppm). 5,971 meta-
bolic features were detected in urine in positive ESI mode by
RPLC-MS (Fig. 5A). HILIC-MS enabled the detection of 2,491
new distinct metabolic features (42%) not detected with
RPLC-MS. In negative ESI mode, 2,837 new distinct meta-
bolic features were detected with HILIC ( 47%). Therefore,
using HILIC in combination with RPLC expanded the
metabolome coverage of urine by 44% compared with
RPLC alone. For plasma, HILIC enabled the detection of
2,100 (68%) and 2,826 (148%) new distinct metabolic
features in positive and negative ESI modes, respectively.
Hence, HILIC dramatically expanded the metabolome cov-
erage of plasma by 108% compared with RPLC alone.
Interestingly, very few metabolic features were found in
both positive and negative ESI modes, indicating that these
modes detect distinct metabolites (Fig. S8A) (41, 50). Alto-
gether, combining the optimized HILIC- and RPLC-MS an-
alytical procedures in positive and negative ESI modes en-
abled the detection of 16,084 and 9,494 distinct metabolic
features in urine and plasma, respectively.
Importantly, the overlapping features detected with both
HILIC- and RPLC-MS were not necessarily of the same quality
in both modes. For example, a metabolite that was eluted in
the void volume zone with RPLC and retained with HILIC will
be of higher quality in the latter because its quantification will
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be more robust and its identification easier. Some examples
including sn-glycero-phosphocholine, carnosine, and L-orni-
thine are presented Fig. S9A. Interestingly, 70% of the over-
lapping metabolic features in urine were retained in HILIC
mode (outside of the void volume zone), indicating that these
metabolites will be of better quality in this mode. Moreover,
50% of the 46 standards eluting in the void volume or with an
unacceptable score in HILIC mode had a good or acceptable
score with RPLC (Fig. 5B). Some examples including
N-acetyl-L-leucine, phenylacetylglycine, and indole-2-carbox-
ylic acid are presented Fig. S9B. In particular, organic acids
and derivatives, amino acids and conjugates, alcohols and
polyols, indoles and derivatives, and acyl glycines were well
resolved with RPLC. However, nucleosides and conjugates as
well as pyridines and derivatives eluted in the void volume
with both systems. As already shown above, steroids and
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derivatives as well as fatty acids and conjugates that were not
eluted from Hypersil GOLD column were well resolved with
Zorbax SB aq (Fig. 3A). Altogether, 88% of the 174 analyzed
standards had a good or acceptable score when ZIC-HILIC
and Hypersil GOLD columns are used in combination (Fig.
S8B).
DISCUSSION
Most untargeted metabolomic studies of urine and plasma
are performed by RPLC-MS alone and often with suboptimal
conditions. This observation motivated us to find an optimal
chromatographic solution involving orthogonal HILIC and
RPLC coupled to mass spectrometry that will enable the
optimal reproducible coverage of human urine and plasma
metabolites. First, we systematically investigated the perform-
ance of five HILIC columns with different chemistry operated
at three different pH using model compounds and biological
samples. We have focused our efforts on varying the nature of
the stationary phase and the mobile phase pH because sev-
eral studies describing the development of HILIC methods
have indicated that they are the two most critical parameters
for tuning metabolite retention, peak shape, and MS signal
intensity (23, 24, 37). Indeed, these two parameters will dic-
tate the amount and type of forces involved in the retention
mechanism of the metabolites. In the context of global met-
abolic profiling, they will impact the quantity and the quality of
detected metabolic features. The zwitterionic column ZIC-
HILIC operated at neutral pH was superior for separating urine
and plasma metabolites with the best peak shape in many
cases. Even though the gradient condition, the oven temper-
ature, and the flow rate have been shown to be secondary
parameters (37), they were also optimized in HILIC mode.
Additionally, we explored the performance of five C18-
bonded silica RPLC columns using standards of varying hy-
drophobicity and biological samples. Hypersil GOLD and Zor-
bax SB aq columns gave the optimal results for urine and
plasma, respectively.
Importantly, after adequate equilibration and conditioning
the optimized HILIC method showed excellent intrabatch re-
producibility of both retention time and peak area that was
similar to those of RPLC-MS procedures. Also, even though
more variable, HILIC- and RPLC-MS procedures exhibited
similarly good long-term (40 days) interbatch reproducibility.
The difference between intra- and long-term interbatch ro-
bustness of HILIC-MS was presumably not due to sample
degradation during storage because HILIC- and RPLC-MS
analyses were performed with the same samples and
RPLC-MS interbatch variability was lower. The number of
features extracted from the two batches with HILIC-MS was
significantly lower on the second batch (3,331 on day 4 com-
pared with 2,325 features on day 46) (Fig. S6A). This differ-
ence was due to the degradation of the condition of the HILIC
column presumably because of the repeated injection of salts
contained in urine samples. This degradation caused peak
broadening and impacted sensitivity since some low abun-
dance features dropped below the intensity threshold. De-
spite a clear loss of sensitivity, intrabatch peak area repro-
ducibility on day 46 was as good as on day 4 (Fig. 4B). The
repeated injection of salts on RPLC column did not impact its
condition because unlike HILIC columns, salts are not re-
tained on RPLC columns. Hence, the Hypersil GOLD column
performed similarly between the two batches; 4,150 aligned
features on day 1 compared with 4,174 on day 39 with similar
retention time and peak area reproducibility (Fig. 4B and Fig.
S6B). A significant concern for large-scale metabolomic stud-
ies is the interbatch normalization of the data. Indeed, the
interbatch variability of untargeted analyses cannot be easily
corrected by using a small number of internal standards be-
cause the signal drift is nonlinear and depends on each me-
tabolite (51). Some data-driven normalization methods have
shown to be efficient (15, 51), and in our case, the cubic spline
normalization enabled to obtain the lowest interbatch peak
area CV (Figs. S7B and 7C).
Finally, the complementarity of the optimized HILIC- and
RPLC-MS analytical procedures in positive and negative ESI
modes was evaluated for urine and plasma samples. Com-
bining the optimized HILIC- and RPLC-MS was found to
greatly expand the metabolome coverage compared with
RPLC alone with 44% and 108% new metabolic features
detected enabling the monitoring of over 16,000 and 9,000
distinct features in urine and plasma, respectively. We, there-
fore, believe that using these optimized analytical procedures
will enable more comprehensive untargeted metabolic studies
of human body fluids and thus will be of great value for
monitoring and discovering metabolic markers of health and
disease and for providing insights into human physiology.
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